¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.
¼¼°èÀÇ ¼Ò¾çÁõ Ä¡·áÁ¦ ½ÃÀå ¼ºÀå°ú µ¿Çâ
Grand View Research, Inc.ÀÇ ÃֽŠº¸°í¼¿¡ µû¸£¸é, ¼¼°èÀÇ ¼Ò¾çÁõ Ä¡·áÁ¦ ½ÃÀå ±Ô¸ð´Â 2030³â±îÁö 113¾ï 4,000¸¸ ´Þ·¯¿¡ À̸£°í, 2025-2030³â±îÁö CAGRÀº 4.1%¸¦ ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.
¾ÆÅäÇÇ ÇǺο°, ¾Ë·¹¸£±â¼º Á¢ÃË ÇǺο°, µÎµå·¯±â À¯º´·ü Áõ°¡°¡ ¿¹Ãø ±â°£ µ¿¾È ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù. »õ·Î¿î T¼¼Æ÷ ¼ºê¼¼Æ®, ƯÈ÷ Th17, Th22ÀÇ µ¿Á¤°ú PROTOPIC(Ÿũ·Î¸®¹«½º)ÀÇ Æ¯Çã ¸¸·á µî, °úÇÐÀûÀÎ ¸ÞÄ¿´ÏÁò ÇØ¸í¿¡ ÀÇÇÑ ½ÅÁ¦Ç°ÀÇ µµÀÔÀº ¿¹Ãø ±â°£ Áß, Á¦Á¶¾÷ü¿¡°Ô »õ·Î¿î Ȱ·Î¸¦ ¿ °ÍÀ¸·Î ±â´ëµË´Ï´Ù.
ÄÚ¸£Æ¼ÄÚ½ºÅ×·ÎÀ̵å´Â ¿°Áõ°ú °¡·Á¿òÁõÀ» ¾ïÁ¦ÇÏ¿© °¡·Á¿òÁõ Ä¡·á¿¡ ³ôÀº È¿°ú¸¦ ¹ßÈÖÇϱ⠶§¹®¿¡ 2013³â ÁÖ¿ä Á¦Ç° ºÎ¹®ÀÌ µÇ¾ú½À´Ï´Ù. ÄÚ¸£Æ¼ÄÚ½ºÅ×·ÎÀ̵åÀÇ ±¹¼Ò Àû¿ëÀº ¼Ò¾çÁõÀÇ Ä¡·á ¹× À¯Áö ¿ä¹ý¿¡ ¸Å¿ì È¿°úÀûÀÎ °ÍÀ¸·Î ¹àÇôÁ³½À´Ï´Ù.
¼Ò¾çÁõ Ä¡·áÁ¦ ½ÃÀå º¸°í¼ ÇÏÀ̶óÀÌÆ®
- ÄÚ¸£Æ¼ÄÚ½ºÅ×·ÎÀ̵尡 ½ÃÀåÀ» µ¶Á¡Çϰí 2024³â¿¡´Â 28.1%ÀÇ Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù. Ç×È÷½ºÅ¸¹Î ¾à¹°Àº ¿¹Ãø ±â°£ µ¿¾È »ó´çÇÑ ¼ºÀåÀÌ ¿¹»óµË´Ï´Ù.
- º´¿ø ¾à±¹ÀÌ ½ÃÀåÀ» µ¶Á¡Çϰí 2024³â¿¡´Â 49.8%ÀÇ Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù. ¿Â¶óÀÎ ¾à±¹Àº ¿¹Ãø ±â°£ µ¿¾È CAGR 5.9%¿¡¼ °¡Àå ºü¸¥ ¼ºÀåÀÌ ¿¹ÃøµË´Ï´Ù.
- ºÏ¹ÌÀÇ ¼Ò¾çÁõ Ä¡·áÁ¦ ½ÃÀåÀº 2024³â 38.7%ÀÇ ¼öÀÍ Á¡À¯À²·Î ¼¼°è ½ÃÀåÀ» µ¶Á¡Çß½À´Ï´Ù. ¹Ì±¹ÀÇ ¼Ò¾çÁõ Ä¡·áÁ¦ ½ÃÀåÀº 2024³â 90.1%ÀÇ ¼öÀÍ Á¡À¯À²·Î ºÏ¹ÌÀÇ ¼Ò¾çÁõ Ä¡·áÁ¦ ½ÃÀåÀ» µ¶Á¡Çß½À´Ï´Ù.
- ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ¼Ò¾çÁõ Ä¡·áÁ¦ ½ÃÀåÀº ¿¹Ãø ±â°£ µ¿¾È °¡Àå ºü¸¥ CAGR 6.1%¸¦ ±â·ÏÇÒ Àü¸ÁÀÔ´Ï´Ù. ¾Æ½Ã¾ÆÅÂÆò¾ç ½ÃÀå Áß ÀεµÀÇ ¼Ò¾çÁõ Ä¡·áÁ¦ ½ÃÀåÀº ¿¹Ãø ±â°£ µ¿¾È °¡Àå ºü¸¥ ¼Óµµ·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.
¸ñÂ÷
Á¦1Àå Á¶»ç ¹æ¹ý°ú ¹üÀ§
Á¦2Àå ÁÖ¿ä ¿ä¾à
Á¦3Àå ¼Ò¾çÁõ Ä¡·áÁ¦ ½ÃÀåÀÇ º¯¼ö, µ¿Çâ, ¹üÀ§
- ½ÃÀå °èÅëÀÇ Àü¸Á
- ½ÃÀå ¿ªÇÐ
- ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ ºÐ¼®
- ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ ºÐ¼®
- ºñÁî´Ï½º ȯ°æ ºÐ¼®
- »ê¾÷ ºÐ¼® - Porter's Five Forces ºÐ¼®
- PESTLE ºÐ¼®
Á¦4Àå ¼Ò¾çÁõ Ä¡·áÁ¦ ½ÃÀå : Áúȯ ºñÁî´Ï½º ºÐ¼®
- Áúº´ ½ÃÀå Á¡À¯À², 2024³â°ú 2030³â
- Áúº´ ºÎ¹® ´ë½Ãº¸µå
- ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø°ú µ¿Ç⠺м®, Áúȯº°, 2018-2030³â
- ¾ÆÅäÇÇ ÇǺο°
- ¾Ë·¹¸£±â¼º Á¢ÃË ÇǺο°
- µÎµå·¯±â
- ±âŸ
Á¦5Àå ¼Ò¾çÁõ Ä¡·áÁ¦ ½ÃÀå : Á¦Ç° ºñÁî´Ï½º ºÐ¼®
- Á¦Ç° ½ÃÀå Á¡À¯À², 2024³â°ú 2030³â
- Á¦Ç° ºÎ¹® ´ë½Ãº¸µå
- ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø°ú µ¿Ç⠺м®, Á¦Ç°º°, 2018-2030³â
- ÄÚ¸£Æ¼ÄÚ½ºÅ×·ÎÀ̵å
- Ç×È÷½ºÅ¸¹ÎÁ¦
- ±¹¼Ò ¸¶ÃëÁ¦
- Ç×ÀÚ±ØÁ¦
- ¸é¿ª ¾ïÁ¦Á¦
- Ä®½Ã´º¸° ¾ïÁ¦Á¦
- ±âŸ
Á¦6Àå ¼Ò¾çÁõ Ä¡·áÁ¦ ½ÃÀå : À¯Åë ä³Î ºñÁî´Ï½º ºÐ¼®
- À¯Åë ä³Î ½ÃÀå Á¡À¯À², 2024³â°ú 2030³â
- À¯Åë ä³Î ºÎ¹® ´ë½Ãº¸µå
- ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø°ú µ¿Ç⠺м®, À¯Åë ä³Îº°, 2018-2030³â
- º´¿ø ¾à±¹
- ¼Ò¸Å ¾à±¹
- ¿Â¶óÀÎ ¾à±¹
Á¦7Àå ¼Ò¾çÁõ Ä¡·áÁ¦ ½ÃÀå : Áö¿ªº°, ÃßÁ¤ ¹× µ¿Ç⠺м®
- Áö¿ªº° ½ÃÀå Á¡À¯À² ºÐ¼®, 2024³â°ú 2030³â
- Áö¿ªº° ½ÃÀå ´ë½Ãº¸µå
- ½ÃÀå ±Ô¸ð, ¿¹Ãø µ¿Ç⠺м®, 2018-2030³â
- ºÏ¹Ì
- ±¹°¡º°, 2018-2030³â
- ¹Ì±¹
- ij³ª´Ù
- ¸ß½ÃÄÚ
- À¯·´
- ±¹°¡º°, 2018-2030³â
- ¿µ±¹
- µ¶ÀÏ
- ÇÁ¶û½º
- ÀÌÅ»¸®¾Æ
- ½ºÆäÀÎ
- ³ë¸£¿þÀÌ
- µ§¸¶Å©
- ½º¿þµ§
- ¾Æ½Ã¾ÆÅÂÆò¾ç
- ±¹°¡º°, 2018-2030³â
- ÀϺ»
- Áß±¹
- Àεµ
- Çѱ¹
- È£ÁÖ
- ű¹
- ¶óƾ¾Æ¸Þ¸®Ä«
- ±¹°¡º°, 2018-2030³â
- ºê¶óÁú
- ¾Æ¸£ÇîÆ¼³ª
- Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
- ±¹°¡º°, 2018-2030³â
- ³²¾ÆÇÁ¸®Ä«
- »ç¿ìµð¾Æ¶óºñ¾Æ
- ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
- Äí¿þÀÌÆ®
Á¦8Àå °æÀï ±¸µµ
- Âü°¡ÀÚ °³¿ä
- ±â¾÷ÀÇ ½ÃÀå Æ÷Áö¼Å´× ºÐ¼®
- ±â¾÷ ºÐ·ù
- Àü·« ¸ÅÇÎ
- ±â¾÷ ÇÁ·ÎÆÄÀÏ/»óÀå ±â¾÷
- AbbVie Inc.
- Amgen, Inc.
- Astellas Pharma Inc.
- Bristol-Myers Squibb
- Cara Therapeutics
- GSK plc
- Novartis AG
- Pfizer Inc.
- Sanofi
- Teva Pharmaceutical Industries Ltd
JHS 25.04.11
Pruritus Therapeutics Market Growth & Trends:
The global Pruritus Therapeutics market size is expected to reach USD 11.34 billion by 2030, registering a CAGR of 4.1% from 2025 to 2030, according to a new report by Grand View Research, Inc. Growing worldwide prevalence of atopic dermatitis, allergic contact dermatitis, and urticaria is expected to drive market growth during the forecast period. The introduction of new products based on scientific mechanistic understanding such as the identification of new T-cell subsets, particularly Th17, and Th22 and the patent expiration of PROTOPIC (tacrolimus) is expected to open up new avenues for manufacturers to capitalize on over the forecast period.
Corticosteroids were the leading product segment in 2013 owing to high efficacy exhibited by this class of drugs in treating pruritic conditions by reducing inflammation and itching. Topical applications of corticosteroids have been found to be extremely effective in the treatment and maintenance therapies pertaining to pruritus.
Pruritus Therapeutics Market Report Highlights:
- Corticosteroids dominated the market and accounted for a share of 28.1% in 2024. Antihistamines are expected to register significant growth over the forecast period.
- Hospital pharmacies dominated the market and accounted for a share of 49.8% in 2024. Online pharmacies are projected to grow at the fastest CAGR of 5.9% over the forecast period.
- North America pruritus therapeutics market dominated the global market with a revenue share of 38.7% in 2024. The pruritus therapeutics market in the U.S. dominated the North America pruritus therapeutics market with a revenue share of 90.1% in 2024.
- Asia Pacific pruritus therapeutics market is expected to register the fastest CAGR of 6.1% in the forecast period. India pruritus therapeutics market is expected to grow at the fastest rate over the forecast period in the Asia Pacific market.
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.2. Segment Definitions
- 1.2.1. Disease
- 1.2.2. Product
- 1.2.3. Distribution Channel
- 1.3. Estimates and Forecast Timeline
- 1.4. Research Methodology
- 1.5. Information Procurement
- 1.5.1. Purchased Database
- 1.5.2. GVR's Internal Database
- 1.5.3. Secondary Sources
- 1.5.4. Primary Research
- 1.6. Information Analysis
- 1.6.1. Data Analysis Models
- 1.7. Market Formulation & Data Visualization
- 1.8. Model Details
- 1.8.1. Commodity Flow Analysis
- 1.9. List of Secondary Sources
- 1.10. Objectives
Chapter 2. Executive Summary
- 2.1. Market Snapshot
- 2.2. Segment Snapshot
- 2.3. Competitive Landscape Snapshot
Chapter 3. Pruritus Therapeutics Market Variables, Trends, & Scope
- 3.1. Market Lineage Outlook
- 3.2. Market Dynamics
- 3.2.1. Market Driver Analysis
- 3.2.2. Market Restraint Analysis
- 3.3. Business Environment Analysis
- 3.3.1. Industry Analysis - Porter's Five Forces Analysis
- 3.3.1.1. Supplier Power
- 3.3.1.2. Buyer Power
- 3.3.1.3. Substitution Threat
- 3.3.1.4. Threat of New Entrants
- 3.3.1.5. Competitive Rivalry
- 3.3.2. PESTLE Analysis
Chapter 4. Pruritus Therapeutics Market: Disease Business Analysis
- 4.1. Disease Market Share, 2024 & 2030
- 4.2. Disease Segment Dashboard
- 4.3. Market Size & Forecasts and Trend Analysis, by Disease, 2018 to 2030 (USD Million)
- 4.4. Atopic Dermatitis
- 4.4.1. Atopic Dermatitis Market, 2018 - 2030 (USD Million)
- 4.5. Allergic Contact Dermatitis
- 4.5.1. Allergic Contact Dermatitis Market, 2018 - 2030 (USD Million)
- 4.6. Urticaria
- 4.6.1. Urticaria Market, 2018 - 2030 (USD Million)
- 4.7. Others
- 4.7.1. Others Market, 2018 - 2030 (USD Million)
Chapter 5. Pruritus Therapeutics Market: Product Business Analysis
- 5.1. Product Market Share, 2024 & 2030
- 5.2. Product Segment Dashboard
- 5.3. Market Size & Forecasts and Trend Analysis, by Product, 2018 to 2030 (USD Million)
- 5.4. Corticosteroids
- 5.4.1. Corticosteroids Market, 2018 - 2030 (USD Million)
- 5.5. Antihistamines
- 5.5.1. Antihistamines Market, 2018 - 2030 (USD Million)
- 5.6. Local Anesthetics
- 5.6.1. Local Anesthetics Market, 2018 - 2030 (USD Million)
- 5.7. Counterirritants
- 5.7.1. Counterirritants Market, 2018 - 2030 (USD Million)
- 5.8. Immunosuppressant
- 5.8.1. Immunosuppressant Market, 2018 - 2030 (USD Million)
- 5.9. Calcineurin Inhibitors
- 5.9.1. Calcineurin Inhibitors Market, 2018 - 2030 (USD Million)
- 5.10. Others
- 5.10.1. Others Market, 2018 - 2030 (USD Million)
Chapter 6. Pruritus Therapeutics Market: Distribution Channel Business Analysis
- 6.1. Distribution Channel Market Share, 2024 & 2030
- 6.2. Distribution Channel Segment Dashboard
- 6.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2018 to 2030 (USD Million)
- 6.4. Hospital Pharmacies
- 6.4.1. Hospital Pharmacies Market, 2018 - 2030 (USD Million)
- 6.5. Retail Pharmacies
- 6.5.1. Retail Pharmacies Market, 2018 - 2030 (USD Million)
- 6.6. Online Pharmacies
- 6.6.1. Online Pharmacies Market, 2018 - 2030 (USD Million)
Chapter 7. Pruritus Therapeutics Market: Regional Estimates & Trend Analysis
- 7.1. Regional Market Share Analysis, 2024 & 2030
- 7.2. Regional Market Dashboard
- 7.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
- 7.4. North America
- 7.4.1. North America Pruritus Therapeutics Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
- 7.4.2. U.S.
- 7.4.2.1. Key Country Dynamics
- 7.4.2.2. Regulatory Framework
- 7.4.2.3. Competitive Insights
- 7.4.2.4. U.S. Pruritus Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 7.4.3. Canada
- 7.4.3.1. Key Country Dynamics
- 7.4.3.2. Regulatory Framework
- 7.4.3.3. Competitive Insights
- 7.4.3.4. Canada Pruritus Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 7.4.4. Mexico
- 7.4.4.1. Key Country Dynamics
- 7.4.4.2. Regulatory Framework
- 7.4.4.3. Competitive Insights
- 7.4.4.4. Mexico Pruritus Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 7.5. Europe
- 7.5.1. Europe Pruritus Therapeutics Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
- 7.5.2. UK
- 7.5.2.1. Key Country Dynamics
- 7.5.2.2. Regulatory Framework
- 7.5.2.3. Competitive Insights
- 7.5.2.4. UK Pruritus Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 7.5.3. Germany
- 7.5.3.1. Key Country Dynamics
- 7.5.3.2. Regulatory Framework
- 7.5.3.3. Competitive Insights
- 7.5.3.4. Germany Pruritus Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 7.5.4. France
- 7.5.4.1. Key Country Dynamics
- 7.5.4.2. Regulatory Framework
- 7.5.4.3. Competitive Insights
- 7.5.4.4. France Pruritus Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 7.5.5. Italy
- 7.5.5.1. Key Country Dynamics
- 7.5.5.2. Regulatory Framework
- 7.5.5.3. Competitive Insights
- 7.5.5.4. Italy Pruritus Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 7.5.6. Spain
- 7.5.6.1. Key Country Dynamics
- 7.5.6.2. Regulatory Framework
- 7.5.6.3. Competitive Insights
- 7.5.6.4. Spain Pruritus Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 7.5.7. Norway
- 7.5.7.1. Key Country Dynamics
- 7.5.7.2. Regulatory Framework
- 7.5.7.3. Competitive Insights
- 7.5.7.4. Norway Pruritus Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 7.5.8. Denmark
- 7.5.8.1. Key Country Dynamics
- 7.5.8.2. Regulatory Framework
- 7.5.8.3. Competitive Insights
- 7.5.8.4. Denmark Pruritus Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 7.5.9. Sweden
- 7.5.9.1. Key Country Dynamics
- 7.5.9.2. Regulatory Framework
- 7.5.9.3. Competitive Insights
- 7.5.9.4. Sweden Pruritus Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 7.6. Asia Pacific
- 7.6.1. Asia Pacific Pruritus Therapeutics Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
- 7.6.2. Japan
- 7.6.2.1. Key Country Dynamics
- 7.6.2.2. Regulatory Framework
- 7.6.2.3. Competitive Insights
- 7.6.2.4. Japan Pruritus Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 7.6.3. China
- 7.6.3.1. Key Country Dynamics
- 7.6.3.2. Regulatory Framework
- 7.6.3.3. Competitive Insights
- 7.6.3.4. China Pruritus Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 7.6.4. India
- 7.6.4.1. Key Country Dynamics
- 7.6.4.2. Regulatory Framework
- 7.6.4.3. Competitive Insights
- 7.6.4.4. India Pruritus Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 7.6.5. South Korea
- 7.6.5.1. Key Country Dynamics
- 7.6.5.2. Regulatory Framework
- 7.6.5.3. Competitive Insights
- 7.6.5.4. South Korea Pruritus Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 7.6.6. Australia
- 7.6.6.1. Key Country Dynamics
- 7.6.6.2. Regulatory Framework
- 7.6.6.3. Competitive Insights
- 7.6.6.4. Australia Pruritus Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 7.6.7. Thailand
- 7.6.7.1. Key Country Dynamics
- 7.6.7.2. Regulatory Framework
- 7.6.7.3. Competitive Insights
- 7.6.7.4. Thailand Pruritus Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 7.7. Latin America
- 7.7.1. Latin America Pruritus Therapeutics Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
- 7.7.2. Brazil
- 7.7.2.1. Key Country Dynamics
- 7.7.2.2. Regulatory Framework
- 7.7.2.3. Competitive Insights
- 7.7.2.4. Brazil Pruritus Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 7.7.3. Argentina
- 7.7.3.1. Key Country Dynamics
- 7.7.3.2. Regulatory Framework
- 7.7.3.3. Competitive Insights
- 7.7.3.4. Argentina Pruritus Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 7.8. MEA
- 7.8.1. MEA Pruritus Therapeutics Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
- 7.8.2. South Africa
- 7.8.2.1. Key Country Dynamics
- 7.8.2.2. Regulatory Framework
- 7.8.2.3. Competitive Insights
- 7.8.2.4. South Africa Pruritus Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 7.8.3. Saudi Arabia
- 7.8.3.1. Key Country Dynamics
- 7.8.3.2. Regulatory Framework
- 7.8.3.3. Competitive Insights
- 7.8.3.4. Saudi Arabia Pruritus Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 7.8.4. UAE
- 7.8.4.1. Key Country Dynamics
- 7.8.4.2. Regulatory Framework
- 7.8.4.3. Competitive Insights
- 7.8.4.4. UAE Pruritus Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 7.8.5. Kuwait
- 7.8.5.1. Key Country Dynamics
- 7.8.5.2. Regulatory Framework
- 7.8.5.3. Competitive Insights
- 7.8.5.4. Kuwait Pruritus Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
Chapter 8. Competitive Landscape
- 8.1. Participant Overview
- 8.2. Company Market Position Analysis
- 8.3. Company Categorization
- 8.4. Strategy Mapping
- 8.5. Company Profiles/Listing
- 8.5.1. AbbVie Inc.
- 8.5.1.1. Overview
- 8.5.1.2. Financial Performance
- 8.5.1.3. Product Benchmarking
- 8.5.1.4. Strategic Initiatives
- 8.5.2. Amgen, Inc.
- 8.5.2.1. Overview
- 8.5.2.2. Financial Performance
- 8.5.2.3. Product Benchmarking
- 8.5.2.4. Strategic Initiatives
- 8.5.3. Astellas Pharma Inc.
- 8.5.3.1. Overview
- 8.5.3.2. Financial Performance
- 8.5.3.3. Product Benchmarking
- 8.5.3.4. Strategic Initiatives
- 8.5.4. Bristol-Myers Squibb
- 8.5.4.1. Overview
- 8.5.4.2. Financial Performance
- 8.5.4.3. Product Benchmarking
- 8.5.4.4. Strategic Initiatives
- 8.5.5. Cara Therapeutics
- 8.5.5.1. Overview
- 8.5.5.2. Financial Performance
- 8.5.5.3. Product Benchmarking
- 8.5.5.4. Strategic Initiatives
- 8.5.6. GSK plc
- 8.5.6.1. Overview
- 8.5.6.2. Financial Performance
- 8.5.6.3. Product Benchmarking
- 8.5.6.4. Strategic Initiatives
- 8.5.7. Novartis AG
- 8.5.7.1. Overview
- 8.5.7.2. Financial Performance
- 8.5.7.3. Product Benchmarking
- 8.5.7.4. Strategic Initiatives
- 8.5.8. Pfizer Inc.
- 8.5.8.1. Overview
- 8.5.8.2. Financial Performance
- 8.5.8.3. Product Benchmarking
- 8.5.8.4. Strategic Initiatives
- 8.5.9. Sanofi
- 8.5.9.1. Overview
- 8.5.9.2. Financial Performance
- 8.5.9.3. Product Benchmarking
- 8.5.9.4. Strategic Initiatives
- 8.5.10. Teva Pharmaceutical Industries Ltd
- 8.5.10.1. Overview
- 8.5.10.2. Financial Performance
- 8.5.10.3. Product Benchmarking
- 8.5.10.4. Strategic Initiatives